Disadvantages and Disadvantages of Capisetinib Tablets/Caposetinib

Capivasertib tablets/Capivasertib (Capivasertib) has made remarkable progress in the field of targeted therapy, especially for breast cancer. It has broad-spectrum anti-cancer potential, but it still has a series of limitations that cannot be ignored. First of all, it is sensitive to PIK3CA, AKT1, PTEN and other gene mutation backgrounds. If the patient does not have the above molecular characteristics, the efficacy of the drug may be significantly reduced. Therefore, without precise molecular testing, the use of capositinib may lead to unstable treatment effects or even ineffective treatment.

Secondly, drug side effects are still prominent. Clinically, some patients experience severe diarrhea, rash, fatigue, hyperglycemia and other adverse reactions after using capositinib, which is related to its extensive inhibition of the AKT pathway. In elderly patients or those with underlying medical conditions, these side effects may further affect quality of life and increase hospitalization rates. In addition, capositinib has not yet been widely covered by medical insurance, the original drug is expensive, and the cost of use poses a large financial burden to ordinary patients, especially when it has not been included in the national drug catalog.

Third, from the perspective of drug stability and treatment course controllability, capositinib is an oral tablet and requires high patient compliance. Once a dose is missed or the dose is unstable, the efficacy may fluctuate. Moreover, after long-term use, the efficacy may be reduced due to drug resistance, and more expensive or complex treatment options need to be replaced. There is currently a lack of unified guidelines for dealing with tumor drug resistance mechanisms.

Finally, the drug is still in the stage of gradual promotion, and there is insufficient relevant clinical long-term survival data. Especially in some rare cancer types, there is a lack of sufficient samples to verify its safety and efficacy. Therefore, although capositinib shows good prospects in people with specific mutations, the overall drug still faces practical problems such as large individual differences, difficult side effects management, and high long-term costs. It needs to be used with caution under professional guidance, and attention should be paid to the research and development trends of the subsequent new generation of AKT pathway-targeted drugs.

Reference materials:https://www.drugs.com/mtm/capivasertib.html